Internal Medicine, Hematology & Oncology · Houston, TX
NPI
1427203819
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
7789 Southwest Fwy Ste 460
Houston, TX, 77074
Phone (713) 778-0300
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.6M
98,132 services
Medicare patients, 2024
252
Average age 75
Drug cost, 2024
$8.8M
2,752 prescriptions
Company payments, 2025
$3,739
From 44 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kathy Sam was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 33,660 times for 25 patients. In total Kathy Sam billed 98,132 services in 97 codes, and Medicare paid $1.6M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-03-18.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 33,660 | 25 | $0.26 | $8,914 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 4,720 | 12 | $6.30 | $30K |
| 85025 Blood Count | Office | 739 | 203 | $7.61 | $5,624 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 690 | 13 | $0.73 | $500 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 620 | 13 | $0.09 | $56.16 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 250 | 137 | $12.89 | $3,223 |
| 99213 Office E&M - Established | Office | 241 | 150 | $61.12 | $15K |
| 96372 Injection Administration | Office | 227 | 31 | $10.74 | $2,437 |
| 99214 Office E&M - Established | Office | 225 | 121 | $95.24 | $21K |
| 96413 Chemotherapy Administration | Office | 190 | 25 | $98.85 | $19K |
| 96367 Intravenous Infusion, Hydration | Office | 125 | 23 | $21.41 | $2,676 |
| 99215 Office E&M - Established | Office | 90 | 51 | $139.50 | $13K |
| 96365 Intravenous Infusion, Hydration | Office | 80 | 37 | $46.20 | $3,696 |
| 96375 Injection Administration | Office | 68 | 13 | $11.73 | $798 |
| 99211 Office E&M - Established | Office | 58 | 15 | $17.74 | $1,029 |
By year: 2022 $1.2M for 85,298 services; 2023 $1.3M for 83,975 services; 2024 $1.6M for 98,132 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 739 | 203 | $7.61 | $5,624 |
| 80047 Clinical Chemistry | 36 | 11 | $13.46 | $485 |
| 81002 Clinical Chemistry | 25 | 11 | $3.41 | $85.25 |
| 36415 Venipuncture Blood Collection | 23 | 19 | $8.65 | $199 |
Medicare prescription drug claims, 2024
In 2024, the drug Kathy Sam prescribed most often to Medicare patients was Letrozole, with 213 prescriptions and refills. In total Kathy Sam wrote 2,752 Medicare prescriptions that cost $8.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 213 | 593 | 76 | $4,564 |
| Eliquis Apixaban | 105 | 117 | 21 | $66K |
| Anastrozole Generic | 98 | 244 | 31 | $1,710 |
| Dexamethasone Generic | 92 | 110 | 49 | $1,822 |
| Ondansetron Odt Ondansetron | 90 | 90 | 68 | $2,447 |
| Verzenio Abemaciclib | 90 | 90 | 13 | $1.4M |
| Prednisone Generic | 83 | 97 | 22 | $387 |
| Procrit Epoetin Alfa | 73 | 73 | 17 | $72K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 72 | 72 | 24 | $1,949 |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 72 | 72 | 58 | $734 |
| Levothyroxine Sodium Generic | 67 | 169 | 19 | $673 |
| Ibrance Palbociclib | 64 | 64 | Under 11 | $945K |
| Aranesp Darbepoetin Alfa In Polysorbat | 63 | 64 | 16 | $97K |
| Granisetron Hcl Generic | 60 | 60 | 49 | $30K |
| Warfarin Sodium Generic | 59 | 93 | Under 11 | $642 |
Brand drugs: 918 claims; generic drugs: 1,834 claims; opioid claims: 135.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kathy Sam $3,739 ($3,739 in general payments such as food, travel and fees) from 44 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $352.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 13 | $352 |
| Abbvie Inc. ABBV | 4 | $313 |
| Janssen Biotech, Inc. JNJ | 7 | $211 |
| E.R. Squibb & Sons, L.L.C. BMY | 9 | $201 |
| Pfizer Inc. PFE | 7 | $180 |
| Merck Sharp & Dohme LLC MRK | 7 | $171 |
| Lilly USA, LLC LLY | 8 | $154 |
| GlaxoSmithKline, LLC. GSK | 6 | $146 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $117 |
| Celgene Corporation BMY | 4 | $108 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.